On 3 March 2021, the TB Europe Coalition and the Regional Expert Group on Migration and Health in Eastern Europe and Central Asia (EECA) co-hosted a webinar addressing the barriers migrants face when accessing TB and healthcare services across the EECA countries and the challenges for service delivery.

RESIST-TB released its March 2021 newsletter with the latest research publications on drug-resistant TB.

In order to support country programmes, healthcare providers, communities, people affected by TB, and partners during the COVID-19 pandemic, the Stop TB Partnership’s External Affairs & Strategic Initiatives team, as part of its Re-imagining TB Care initiative, is organizing a series of Virtual Innovation Spotlights to present and share various digital and health technologies that can be used to:

TOKYO and NEW YORK (March 31, 2021) — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and TB Alliance (President and CEO: Mel Spigelman, M.D.), a non-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis (TB) today announced that they have entered into a new collaborative research (“Hit-to-Lead PJ”) agreement to identify lead compounds for the treatment of TB.

For the third year, Treatment Action Group (TAG), with support from the IMPAACT4TB project, is organizing a self-guided Moodle online training course (2 May - 6 June 2021), TB Preventive Treatment | Fundamentals for Activists!, open to any members of TB civil society and communities. The course equips activists with everything they need to know to advocate for the highest-attainable standard of TB preventive treatment.

The TB Europe Coalition released a policy brief aiming to increase the meaningful engagement of civil society organizations and TB affected communities in the implementation of the Multisectoral Accountability Framework on TB in the time of COVID-19 pandemic in the Eastern Europe and Central Asia (EECA) region.

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).

Clinical trials of BATM’s new method for the rapid and comprehensive diagnosis of TB will be fully funded by the Stop TB Partnership.

In clinical trials, a time-honored but old-school way to determine if TB is being knocked out by antibiotics involves having study participants cough up phlegm for a sputum culture, a test that can gauge whether the bacteria are succumbing to—or resisting—treatment.

The World Health Organization (WHO) Global TB Program has initiated a process to update the consolidated guidelines on the treatment of drug-resistant TB (DR-TB). The WHO Global TB Program is seeking support from independent researchers, academic institutions or other entities with relevant expertise and experience in systematic review and statistical analysis to perform the synthesis and analysis of the available data on new DR-TB treatment regimens for the guideline update.